Author

Joanna Dawes

Observed names: Dawes, Joanna, Dawes, Joanna Camilla, J.C. Dawes, Joanna C Dawes, Joanna C. Dawes

Institution: Autolus (United Kingdom)

Observed institutions: Institute of Cancer Research, Royal Marsden Hospital, Autolus (United Kingdom), MRC London Institute of Medical Sciences, Imperial College London, Medical Research Council

OpenAlex ID: A5081319975

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

2018 · B. Basu, M.G. Krebs, et al. · Annals of Oncology · 33

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

2017 · Maxime Chenard-Poirier, Martin Kaiser, et al. · Journal of Clinical Oncology · 31

LUMI-PCR: an Illumina platform ligation-mediated PCR protocol for integration site cloning, provides molecular quantitation of integration sites

2020 · Joanna C. Dawes, Philip Webster, et al. · Mobile DNA · 11

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

2023 · Claire Roddie, Eleni Tholouli, et al. · Blood · 5

Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates

2018 · Philip Webster, Joanna C. Dawes, et al. · Nature Communications · 3

P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC

2017 · Matthew Krebs, James Spicer, et al. · Journal of Thoracic Oncology · 3

Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas

2021 · Joanna C. Dawes, Anthony G. Uren · Frontiers in Immunology · 2

Author Correction: Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates

2019 · Philip Webster, Joanna C. Dawes, et al. · Nature Communications · 1

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma

2018 · Priya Sriskandarajah, Kevin Boyd, et al. · Blood · 1

S262: Safety and Efficacy of Obecabtagene Autoleucel (obe-cel), a Fast-off Rate Cd19 Car in Relapsed/refractory Adult B-cell Acute Lymphoblastic Leukaemia:top Line Results of the Pivotal Felix Study

2023 · Claire Roddie, Karamjeet Sandhu, et al. · HemaSphere

Additional file 3 of LUMI-PCR: an Illumina platform ligation-mediated PCR protocol for integration site cloning, provides molecular quantitation of integration sites

2020 · Dawes, Joanna, Webster, Philip, et al. · Figshare

Additional file 2 of LUMI-PCR: an Illumina platform ligation-mediated PCR protocol for integration site cloning, provides molecular quantitation of integration sites

2020 · Dawes, Joanna, Webster, Philip, et al. · Figshare

TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.

2017 · Raghav Sundar, Bristi Basu, et al. · Journal of Clinical Oncology

TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer

2016 · U. Banerji, B. Basu, et al. · Annals of Oncology

Modelling Crebbp loss in BCL2 driven non-Hodgkin’s lymphoma

2015 · Dawes, Joanna Camilla · Spiral (Imperial College London)

Works count: 17

Citation count: 90

H-index: 4

I10-index: 3